(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of 109.03% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Entrada Therapeutics's revenue in 2026 is $5,738,000.On average, 10 Wall Street analysts forecast TRDA's revenue for 2026 to be $871,406,367, with the lowest TRDA revenue forecast at $34,239,783, and the highest TRDA revenue forecast at $2,445,698,808. On average, 10 Wall Street analysts forecast TRDA's revenue for 2027 to be $1,652,477,161, with the lowest TRDA revenue forecast at $133,154,713, and the highest TRDA revenue forecast at $3,464,739,978.
In 2028, TRDA is forecast to generate $1,934,625,398 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $7,133,288,190.